


**REMARKS**

This Preliminary Amendment is being made upon entry of International Application No. PCT/US03/009461 into the U.S. National Phase of prosecution.

In the specification, a new paragraph has been added to the first line of the specification to include the priority information. An Abstract on a separate sheet is attached as required under 37 CFR 1.72(b).

Claims 52-57 have been cancelled without prejudice or disclaimer. Claims 3-18, 20-21, 27, 31-38, 40-44, 46-51 and 58 have been amended to comply with U.S. practice.

Respectfully submitted,




Kathryn L. Sieburth  
Attorney for Applicants  
Registration No. 40,072

GLAXOSMITHKLINE  
Corporate Intellectual Property UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5012  
Facsimile (610) 270-5090

N:\KLS\Cases\P51327P\NatI Stage\preliminary amendment.doc

### **ABSTRACT OF THE DISCLOSURE**

Disclosed is a compound having the formula



pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists.